Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Brexit

Set Alert for Brexit Watch

MHRA ‘Aware Of UK Cliff Edge’ In Post-Brexit Devices Regulation Plan

The UK government’s response to the MHRA consultation on future device regulation will be published very soon. So says the agency’s new health care access officer. But will there be enough time for companies to comply with it?

United Kingdom Regulation

UK MHRA Notes Concern Over Medtech’s Mid-2023 Deadline – But Still No Draft Law Progress

The One Agency initiative, patient safety, methods of funding and recruitment needs were pressing discussion themes during the MHRA’s April 2022 board meeting held in public.

United Kingdom Regulation

Device Makers Are Bucking Decades-Long Trend Of Launching Products In EU. Here’s Why

In this Medtech Insight Q&A, two UCLA-backed study authors argue that the US FDA “has emerged as the global regulatory agency most successful in promoting access to novel medtech products, especially digitally enabled or software-driven ones.”

Innovation Regulation

QUOTED. Phil Brown.

The Medicines and Medical Devices Act presses the UK to create regulations that make the market attractive for business. But striking the right balance in creating the new agency is crucial, said Phil Brown, director of regulation and compliance for the Association of British HealthTech Industries.

Quoted United Kingdom

If You Build It, Will They Come? Vital That UK MHRA Creates Right Environment For Medtechs

The Medicines and Medical Devices Act presses the UK to regulate in such a way that makes the market attractive for industry and investment. Medtech manufacturers insist the MHRA must strike the right balance as it brings its ‘plan for a new agency’ to life, said the ABHI’s Phil Brown, in the second of a two-part industry view of UK medtech’s regulatory future.

United Kingdom Regulation

UKCA Marking Debate Moves To Next Level: All Eyes On The MHRA

The MHRA is under pressure to deliver a new sovereign devices regulatory system in the tightest of timelines for the post-Brexit UK market. It has had no lack of support in this endeavor from system users, but industry is now keen to see the regulator deliver on its two-year plan issued in 2021, says the ABHI’s Phil Brown, in this first part of a two-part industry view of future UK needs.

United Kingdom Regulation

MHRA's Graeme Tunbridge Joins BSI Notified Body

Graeme Tunbridge is looking forward to a new career with notified body, BSI, after nearly two decades as a civil servant. But where does his departure leave the UK MHRA at a time of critical change?

EU Europe

UK Consultation: Device Regulator Seeks To Balance Innovation And Patient Safety

Innovative device access pathways are on the agenda of both NICE and the MHRA, but the UK regulator’s new chief safety officer stresses that patient safety first and foremost will shape its work programs in the post-EU era.

United Kingdom Regulation

Medtech Industry’s Wishlist For MHRA’s New UK Regulatory Structure

The UK's medtech regulatory consultation has closed and the MHRA must now assess the views of stakeholders on the 465 questions designed to help shape the foundations of a future-proofed regulatory system. But time is tight, as speakers at the ABHI’s annual regulatory conference were at pains to stress.

Regulation United Kingdom

UK’s Ambitious Plan For Medtech Regulation Merits Attention

The MHRA’s efforts to give the UK a nimble, responsive, innovation-facing medtech regulatory system earnt high marks from Bristows’ Alex Denoon, who assessed the opportunity at hand during the MedTech Summit.

United Kingdom Regulation

UK Regulator To Lose 20% Of Staff In Post-Brexit Cost-Cutting Plans

The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.

United Kingdom Brexit

MHRA Must Seize UK Digital And Diagnostics Opportunity: ABHI Perspectives On Enabling Regulation – Part 2

IVD and healthtech industry representatives give their views on how the future UK medtech system can be shaped to be agile and responsive to patients’ needs, mindful that the regulator must deliver a standalone regulatory system and functional UKCA marking in less than two years.

United Kingdom Regulation
See All
UsernamePublicRestriction

Register